Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus sufentanil PCIA after autologous skin grafting
ChiCTR2600135323Phase 4Recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Apr 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in postoperative pain comparing Esketamine Combined with Sufentanil Group with Sufentanil Group (2 arms). Primary endpoint: Quality of Recovery-15 (QoR-15) score. Started Apr 2025; status: recruiting.
02
Drugs
esketaminesufentanil
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600135323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135323.